These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 18006614)

  • 21. Using dual-tracer PET to predict the biologic behavior of human colorectal cancer.
    Wang H; Zhang J; Tian J; Qu B; Li T; Chen Y; Liu J; Wang S
    J Nucl Med; 2009 Nov; 50(11):1857-64. PubMed ID: 19837754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 18F-FDG or 3'-deoxy-3'-18F-fluorothymidine to detect transformation of follicular lymphoma.
    Wondergem MJ; Rizvi SN; Jauw Y; Hoekstra OS; Hoetjes N; van de Ven PM; Boellaard R; Chamuleau ME; Cillessen SA; Regelink JC; Zweegman S; Zijlstra JM
    J Nucl Med; 2015 Feb; 56(2):216-21. PubMed ID: 25593118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
    Everitt S; Hicks RJ; Ball D; Kron T; Schneider-Kolsky M; Walter T; Binns D; Mac Manus M
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1098-104. PubMed ID: 19386444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Platinum-Based Chemoradiotherapy on Cellular Proliferation in Bone Marrow and Spleen, Estimated by (18)F-FLT PET/CT in Patients with Locally Advanced Non-Small Cell Lung Cancer.
    Leimgruber A; Möller A; Everitt SJ; Chabrot M; Ball DL; Solomon B; MacManus M; Hicks RJ
    J Nucl Med; 2014 Jul; 55(7):1075-80. PubMed ID: 24868108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [18F]3'-deoxy-3'-fluorothymidine PET for the diagnosis and grading of brain tumors.
    Choi SJ; Kim JS; Kim JH; Oh SJ; Lee JG; Kim CJ; Ra YS; Yeo JS; Ryu JS; Moon DH
    Eur J Nucl Med Mol Imaging; 2005 Jun; 32(6):653-9. PubMed ID: 15711980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model.
    van Waarde A; Cobben DC; Suurmeijer AJ; Maas B; Vaalburg W; de Vries EF; Jager PL; Hoekstra HJ; Elsinga PH
    J Nucl Med; 2004 Apr; 45(4):695-700. PubMed ID: 15073267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma.
    Yamane T; Takaoka A; Kita M; Imai Y; Senda M
    Ann Nucl Med; 2012 Jul; 26(6):478-84. PubMed ID: 22477262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
    Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
    J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study.
    Smyczek-Gargya B; Fersis N; Dittmann H; Vogel U; Reischl G; Machulla HJ; Wallwiener D; Bares R; Dohmen BM
    Eur J Nucl Med Mol Imaging; 2004 May; 31(5):720-4. PubMed ID: 14991243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FLT-PET/CT diagnosis of primary and metastatic nodal lesions of gastric cancer: comparison with FDG-PET/CT.
    Nakajo M; Kajiya Y; Tani A; Jinguji M; Nakajo M; Yoshiura T
    Abdom Radiol (NY); 2016 Oct; 41(10):1891-8. PubMed ID: 27255652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
    Jacobs AH; Thomas A; Kracht LW; Li H; Dittmar C; Garlip G; Galldiks N; Klein JC; Sobesky J; Hilker R; Vollmar S; Herholz K; Wienhard K; Heiss WD
    J Nucl Med; 2005 Dec; 46(12):1948-58. PubMed ID: 16330557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients.
    Troost EG; Vogel WV; Merkx MA; Slootweg PJ; Marres HA; Peeters WJ; Bussink J; van der Kogel AJ; Oyen WJ; Kaanders JH
    J Nucl Med; 2007 May; 48(5):726-35. PubMed ID: 17475960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography.
    Yap CS; Czernin J; Fishbein MC; Cameron RB; Schiepers C; Phelps ME; Weber WA
    Chest; 2006 Feb; 129(2):393-401. PubMed ID: 16478857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
    Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
    Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of colorectal cancer using ¹⁸F-FLT PET: comparison with ¹⁸F-FDG PET.
    Yamamoto Y; Kameyama R; Izuishi K; Takebayashi R; Hagiike M; Asakura M; Haba R; Nishiyama Y
    Nucl Med Commun; 2009 Nov; 30(11):841-5. PubMed ID: 19773672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imaging proliferation in human leukemia-tumor bearing mice with (18)F-FLT: Comparison with (18)F-FDG PET.
    Lu L; Jiang L; Guan H; Gao Y; Lu H
    Hell J Nucl Med; 2012; 15(3):206-9. PubMed ID: 23106052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pilot study of the value of 18F-fluoro-deoxy-thymidine PET/CT in predicting viable lymphoma in residual 18F-FDG avid masses after completion of therapy.
    Mena E; Lindenberg ML; Turkbey BI; Shih J; Logan J; Adler S; Wong K; Wilson W; Choyke PL; Kurdziel KA
    Clin Nucl Med; 2014 Oct; 39(10):874-81. PubMed ID: 25144214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic Value of 18F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18F-FDG PET and Ki-67 in 100 Patients.
    Johnbeck CB; Knigge U; Langer SW; Loft A; Berthelsen AK; Federspiel B; Binderup T; Kjaer A
    J Nucl Med; 2016 Dec; 57(12):1851-1857. PubMed ID: 27469355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Should 18F-FDG PET/CT Be Routinely Performed in the Clinical Staging of Locally Advanced Gastric Adenocarcinoma?
    Perlaza P; Ortín J; Pagès M; Buxó E; Fernández-Esparrach G; Colletti PM; Rubello D; Mayoral M; Sánchez N; Ruiz C; Ginés A; Fuster D
    Clin Nucl Med; 2018 Jun; 43(6):402-410. PubMed ID: 29485442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.